Advanced non small cell lung cancer NSCLC Cisplatin Etoposide Paclitaxel
Conditions
Interventions
Inj. Cisplatin 75 mg/m2 IV Day 1 and Inj. Etoposide 120 mg/m2 IV Day 1 to Day 3
three week regimen,Inj. Paclitaxel 135 mg/m2 IV Day 1 and Inj. Cisplatin 75 mg/m2 IV Day 2
three week regimen
Experimental Drug,Experimental Drug
Arm A-
Cisplatin and Etoposide,Arm B-
Sponsors
Dr. Munshi Md. Arif Hosen
BSMMU,
Shahbag,
Dhaka,
Bangladesh
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with histology confirmed advanced NSCLC - stage IIIB and stage IV includes liver metastasis, metastasis to opposite lung and pleural effusion
Exclusion criteria
Exclusion criteria: •Patients with other than non-small cell lung cancer. •Poor performance status: ECOG score >2. •Those who were not willing. •Age below 18 years and above 70 years. •Patients with history of prior chemotherapy or radiotherapy to the chest. •Initial surgery (excluding diagnostic biopsy) of the primary site. •Patients with double primaries. •Pregnant or lactating woman. •Patient dropped out or lost to follow up before completion of study. •Serious concomitant medical illness including severe cardiac disease, uncontrolled diabetes mellitus, hypertension or renal diseases. •Prisoners.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response 1 year clinical and radiological | — |
Secondary
| Measure | Time frame |
|---|---|
| Toxicity 1 year Clinical and Biochemical | — |
Countries
Bangladesh
Contacts
Public ContactMunshi Md. Hosen
BSMMU, Shahbag, Dhaka
Outcome results
None listed